QoL subscore: The improvement was significant in
Description: QoL subscore: The improvement was significant in fatigue subscore at month 6 (LSMD: 0.31; p0.0229)3 Exploratory results: EPL SoC significantly reduced HbA1C levels compared with placebo SoC at 6 months4 A phase 4 multicenter,
Related Topics
Download Presentation
"QoL subscore: The improvement was significant in" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Presentation Transcript
slide1. QoL subscore:
The improvement was significant in fatigue subscore at month 6 (LSMD: 0.31; p=0.0229)3 Exploratory results:
EPL + SoC significantly reduced HbA1C levels compared with placebo + SoC at 6 months4 A phase 4 multicenter, multinational, double-blind, randomized, placebo-controlled, parallel-group study, conducted in Germany and Poland (study duration was 10 months) EXCEL study design1 Primary outcome:
A statistically significant reduction in CAP score was observed in the EPL vs placebo group at 6 months (p=0.0269)3
Reduction in CAP score was observed as early as 3 months and sustained at 9 months3 CAP, controlled attenuation parameter; CLDQ, chronic liver disease questionnaire; EPL, essential phosphilipids; EXCEL, Exploring Efficacy of Essentiale in Fatty Liver Disease; HbA1c, glycated Haemoglobin A1c; LSMD, least square mean difference; MASH, metabolic-dysfunction associated steatohepatitis; MASLD, metabolic-dysfunction associated steatotic liver disease; MMRM, mixed-effects model with repeated measuresmITT, modified intention-to-treat; QoL, quality of life; SE, standard error; SoC, standard-of-care (lifestyle modification [diet and physical activity/exercise]) ; T2DM, type 2 diabetes mellitus. 1) Stefan N, et al. Trials. 2024;25:374; 2) Gundermann KJ, et al. Pharmacol Rep. 2016;3:643–659; 3) Stefan N, et al. Poster presented at: AASLD; November 15 – 19, 2024; San Diego, CA, USA. (Poster ID: 5037); 4) Stefan N, et al. Poster presented at: SLD-EASL Summit; January 23 – 25, 2025; Estoril, Portugal. (Poster ID: PO7-01). Visit 4 Visit 3 Visit 1 Visit 2 Active ingredient of EPL: 1,2-dilinoleoylphosphatidylcholine (DLPC)2 Arm A: EPL + SoC (N=97) Arm B: Placebo + SoC (N=96) 1:1
R Treatment period 3 months 3 months 3 months First study to systematically assess steatosis and QoL improvement with EPL (Opella®) via CAP and CLDQ-MASLD/MASH questionnaire, respectively, in patients with MASLD associated with T2DM and/or hyperlipidemia and/or obesity1 What is EXCEL clinical trial? Results: Total of 193 patients were enrolled; of these 165 constituted mITT set *P< 0.05; #Analysis was carried out in mITT population using MMRM; The dotted line indicates a 3 months follow-up after end of treatment EPL + SoC, demonstrated significant efficacy in reducing hepatic steatosis, showed overall numerical QoL improvement and significant improvement in the fatigue subgroup, in patients with MASLD at 6 months, compared to placebo + SoC The overall safety profile of EPL + SoC group was comparable with that of placebo + SoC3 Safety EPL improved QoL fatigue subscore * Secondary outcome:
At month 6, CLDQ-MASLD/MASH total score was numerically improved in EPL vs placebo group (LSMD: 0.17; p=0.2445)3 R, randomization PromoMats ID: MAT-GLB-2502572; Date of approval: May 2025 Focusing on metabolic risk of MASLD/MAFLD. EXCEL study design and major outcomes Professor Norbert Stefan
Department of Internal Medicine IV, University Hospital Tübingen, Tübingen, Germany<br>
The improvement was significant in fatigue subscore at month 6 (LSMD: 0.31; p=0.0229)3 Exploratory results:
EPL + SoC significantly reduced HbA1C levels compared with placebo + SoC at 6 months4 A phase 4 multicenter, multinational, double-blind, randomized, placebo-controlled, parallel-group study, conducted in Germany and Poland (study duration was 10 months) EXCEL study design1 Primary outcome:
A statistically significant reduction in CAP score was observed in the EPL vs placebo group at 6 months (p=0.0269)3
Reduction in CAP score was observed as early as 3 months and sustained at 9 months3 CAP, controlled attenuation parameter; CLDQ, chronic liver disease questionnaire; EPL, essential phosphilipids; EXCEL, Exploring Efficacy of Essentiale in Fatty Liver Disease; HbA1c, glycated Haemoglobin A1c; LSMD, least square mean difference; MASH, metabolic-dysfunction associated steatohepatitis; MASLD, metabolic-dysfunction associated steatotic liver disease; MMRM, mixed-effects model with repeated measuresmITT, modified intention-to-treat; QoL, quality of life; SE, standard error; SoC, standard-of-care (lifestyle modification [diet and physical activity/exercise]) ; T2DM, type 2 diabetes mellitus. 1) Stefan N, et al. Trials. 2024;25:374; 2) Gundermann KJ, et al. Pharmacol Rep. 2016;3:643–659; 3) Stefan N, et al. Poster presented at: AASLD; November 15 – 19, 2024; San Diego, CA, USA. (Poster ID: 5037); 4) Stefan N, et al. Poster presented at: SLD-EASL Summit; January 23 – 25, 2025; Estoril, Portugal. (Poster ID: PO7-01). Visit 4 Visit 3 Visit 1 Visit 2 Active ingredient of EPL: 1,2-dilinoleoylphosphatidylcholine (DLPC)2 Arm A: EPL + SoC (N=97) Arm B: Placebo + SoC (N=96) 1:1
R Treatment period 3 months 3 months 3 months First study to systematically assess steatosis and QoL improvement with EPL (Opella®) via CAP and CLDQ-MASLD/MASH questionnaire, respectively, in patients with MASLD associated with T2DM and/or hyperlipidemia and/or obesity1 What is EXCEL clinical trial? Results: Total of 193 patients were enrolled; of these 165 constituted mITT set *P< 0.05; #Analysis was carried out in mITT population using MMRM; The dotted line indicates a 3 months follow-up after end of treatment EPL + SoC, demonstrated significant efficacy in reducing hepatic steatosis, showed overall numerical QoL improvement and significant improvement in the fatigue subgroup, in patients with MASLD at 6 months, compared to placebo + SoC The overall safety profile of EPL + SoC group was comparable with that of placebo + SoC3 Safety EPL improved QoL fatigue subscore * Secondary outcome:
At month 6, CLDQ-MASLD/MASH total score was numerically improved in EPL vs placebo group (LSMD: 0.17; p=0.2445)3 R, randomization PromoMats ID: MAT-GLB-2502572; Date of approval: May 2025 Focusing on metabolic risk of MASLD/MAFLD. EXCEL study design and major outcomes Professor Norbert Stefan
Department of Internal Medicine IV, University Hospital Tübingen, Tübingen, Germany<br>